# Catalio Capital Management

> Catalio Capital Management is a New York investment firm focused on innovative healthcare across venture and growth equity, structured credit, public equities, and co-investments. Its distinguishing asset is a network of 45 venture partners - serial scientist-entrepreneurs who help source companies, test scientific claims, and identify emerging biomedical themes. Founded in 2020 by George Petrocheilos and R. Jacob Vogelstein, Catalio reported $2 billion in assets under management as of October 1, 2025.

- **Founded:** 2020
- **Headquarters:** New York, United States
- **Founders:** George C. Petrocheilos (Co-Founder and Managing Partner), R. Jacob Vogelstein, Ph.D. (Co-Founder and Managing Partner)
- **Team size:** Approximately 39 employees in supplied company data; Catalio also reports 45 venture partners
- **Products:** Catalio Nexus private equity funds, Structured Opportunities, Catalio Public Equities, Co-investments and SPVs, Catalio Global Innovative Healthcare Long/Short UCITS Fund
- **Notable:** Reached $2 billion in assets under management as of October 1, 2025., Built a network of 45 venture partners who collectively founded 171 companies, according to the firm., Closed Nexus Fund IV and related vehicles with more than $400 million in commitments in July 2025.

## Products & services

- **Catalio Nexus private equity funds** — Flagship venture and growth strategy investing in privately held innovative healthcare companies from inception through IPO.
- **Structured Opportunities** — Senior-secured structured financing for healthcare and biomedical companies, designed as an alternative or complement to dilutive equity.
- **Catalio Public Equities** — A long-bias, fundamental equity long/short strategy covering global drugs, devices, diagnostics, and healthcare data companies.
- **Co-investments and SPVs** — Deal-specific access that lets limited partners invest alongside Catalio funds in selected portfolio companies.
- **Catalio Global Innovative Healthcare Long/Short UCITS Fund** — A European-regulated vehicle launched with IAM Investments to broaden access to Catalio's public-equities strategy.

## Achievements

- Reached $2 billion in assets under management as of October 1, 2025.
- Built a network of 45 venture partners who collectively founded 171 companies, according to the firm.
- Closed Nexus Fund IV and related vehicles with more than $400 million in commitments in July 2025.
- Closed an oversubscribed second structured-credit fund with more than $325 million in commitments in January 2026, above its $250 million target.
- Distributed nearly $300 million to investors from funds and SPVs between 2020 and October 2025, according to Catalio.
- Co-founded Haystack Oncology, which Quest Diagnostics acquired in 2023 for up to $450 million.
- Backed Thrive Earlier Detection, acquired by Exact Sciences in a transaction valued at up to $2.15 billion.

## Latest updates

- **2026-07** — Catalio participated in AdvanCell's $315 million Series D financing, according to company-investment tracking data.
- **2026-01** — Closed Catalio Structured Opportunities Fund II and related co-investment vehicles with more than $325 million, exceeding a $250 million target.
- **2025-07** — Closed Catalio Nexus Fund IV and related co-investment vehicles with more than $400 million in commitments.
- **2025-02** — Launched the Catalio Global Innovative Healthcare Long/Short UCITS Fund with IAM Investments.
- **2023-10** — KKR agreed to acquire a minority stake, invest in Catalio funds, and support a strategic advisory board chaired by Henry Kravis.

## Links

- Website: https://www.cataliocapital.com/
- LinkedIn: https://www.linkedin.com/company/catalio-capital
- Twitter/X: https://x.com/CatalioCapital

---

Profile page: https://yespress.io/catalio-capital-management
Published by YesPress — https://yespress.io
Last updated: 2026-08-16